RAPT Therapeutics, Inc. (RAPT) EBIT (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed EBIT for 5 consecutive years, with -$54.5 million as the latest value for Q4 2024.
- Quarterly EBIT fell 63.97% to -$54.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$136.1 million through Dec 2024, down 7.11% year-over-year, with the annual reading at -$136.1 million for FY2024, 7.11% down from the prior year.
- EBIT hit -$54.5 million in Q4 2024 for RAPT Therapeutics, down from -$19.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$12.5 million in Q2 2020 to a low of -$54.5 million in Q4 2024.
- Historically, EBIT has averaged -$23.6 million across 5 years, with a median of -$20.3 million in 2022.
- Biggest YoY gain for EBIT was 41.66% in 2024; the steepest drop was 63.97% in 2024.
- Year by year, EBIT stood at -$13.1 million in 2020, then plummeted by 37.82% to -$18.0 million in 2021, then crashed by 35.47% to -$24.4 million in 2022, then plummeted by 35.96% to -$33.2 million in 2023, then plummeted by 63.97% to -$54.5 million in 2024.
- Business Quant data shows EBIT for RAPT at -$54.5 million in Q4 2024, -$19.8 million in Q3 2024, and -$29.3 million in Q2 2024.